Mind Cure Health Receives Ethics Approval For Psychedelic Integration Protocol Study
Mind Cure Health (CSE: MCUR) has seen its integration protocol research study receive unconditional ethics approval. The study is being conducted in connection with the development of iSTRYM, the firms digital therapeutics platform.
The ethics approval, which comes from Veritas IRB, effectively ensures that processes included in research studies respects participants rights and that they are delivered utilizing the highest standards of ethical practice in human studies. The approval effectively signifies the scientific validation of the study.
The study is being conducted to inform the development of iSTRYM, and how it is built out to best serve therapists, patients, and the psychedelics industry as a whole.
“As we build out iSTRYM to be the largest data repository of psychedelic experiences, we are ensuring that its development is rooted in research proof and a deep understanding of the systems and protocols provided during psychedelic therapy.”
Kelsey Ramsden, CEO of Mind Cure Health
Mind Cure Health last traded at $0.55 on the CSE.
FULL DISCLOSURE: Mind Cure Health is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Mind Cure Health on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.
